OKUR

Onkure Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↓ 4/10
  • Value↓ 3/10
Onkure Therapeutics sales and earnings growth
OKUR Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 71.20%
  • FCF Y/Y↓ -1.38%
Onkure Therapeutics gross and profit margin trends
OKUR Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↑ -5000.50%
Onkure Therapeutics net debt vs free cash flow
OKUR Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -7438.6

Onkure Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks